The invention relates to a chimeric peptide displaying the ganglioside-binding properties of both a-synuclein and ß-amyloid peptide. Such peptide is useful in preventing or treating any condition which involves gangliosides as cell surface receptor sites, including neurodegenerative disorders, infectious diseases, or tumors.